Floatz logo

3 assets in Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions

Therapeutic assets addressing Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cabozantinib
Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions
Australian and New Zealand Urogenital and Prostate Cancer Trials GroupP2B (57)
Axitinib
Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions
National Cancer Institute (NCI)P2CCC (53)
Nivolumab
Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions
National Cancer Institute (NCI)P2CCC (53)